Tianjin Weikai Bioeng., Ltd.   Report issue

For profit Phase 2
Founded: Tianjin China (2009)
Status: No NME R&D (2009)

Organization Overview

First Clinical Trial
2019
NCT03863002
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Tianjin Weikai Bioeng., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

autologous mesenchymal cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute-On-Chronic Liver Failure (Phase 2)

End Stage Liver Disease (Phase 2)

Hepatic Insufficiency (Phase 2)

Liver Failure (Phase 2)

Liver Failure, Acute (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1